COVID-19 rebound after oral treatment in a nursing home facility: A case series
Paxlovid (nirmatrevir/ritonavir) is a 2 drug regimen taken together twice daily for 5 days was authorized for emergency use for nonhospitalized patients who are at risk for the progression of coronavirus disease (COVID-19). However, recurrence of symptoms 2–8 days after completing the treatment cour...
שמור ב:
| Principais autores: | , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2022-12-01
|
| סדרה: | Infectious Medicine |
| נושאים: | |
| גישה מקוונת: | http://www.sciencedirect.com/science/article/pii/S2772431X22000521 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|